Monitoring Requirements for Dimethyl Fumarate Therapy

Baseline and Ongoing Laboratory Tests

• Urinalysis is essential to establish baseline renal function, and serum chemistry profile including renal function tests should be monitored every 2 weeks for the first month, monthly for the first 6 months, and bimonthly thereafter, according to the American Academy of Dermatology 1, 2
• Gastrointestinal effects, such as abdominal cramps, nausea, and diarrhea, should be monitored, as reported by the American Academy of Dermatology 1, 2

Special Considerations

Adverse Effect Monitoring

• The American Academy of Dermatology recommends monitoring for gastrointestinal effects, such as abdominal cramps, nausea, and diarrhea, which are potential adverse effects of dimethyl fumarate therapy 1, 2